Winston Kung
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 30, 2026
Corbus Doses First Patient in CRB-701 TEMPO-1 Study. Corbus Pharmaceuticals announced that the first patient has been dosed in the TEMPO-1 registrational study for CRB-701. This clinical trial focuses on patients with second-line or later oropharyngeal cancer. The update marks a significant step in the development timeline for the company's lead asset.
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 6, 2026
PMV Pharmaceuticals Adds Matt Eckler to Board. PMV Pharmaceuticals has appointed Matt Eckler, Ph.D., to its Board of Directors. This corporate update adds to the company's leadership team. The stock is currently trading near the top of its 52-week range, with an RSI of 69.0 indicating strong recent momentum.
Transaction History
| JANX | ▲ Buy | Grant | 5,500 | $0 | 6/11/2026 | View on chart |
| CRBP | ▼ Sell | Open Market | 2,026 | $16K | 6/10/2026 | View on chart |
| CRBP | ▲ Buy | Grant | 3,800 | $0 | 5/19/2026 | View on chart |
| JANX | ▲ Buy | Grant | 3,750 | $0 | 6/11/2025 | View on chart |
| CRBP | ▲ Buy | Grant | 4,800 | $0 | 5/30/2025 | View on chart |
| CRBP | ▲ Buy | Grant | 5,566 | $0 | 8/16/2024 | View on chart |
| JANX | ▲ Buy | Grant | 2,500 | $0 | 6/26/2024 | View on chart |
| PMVP | ▼ Sell | Gift | 2,560 | $0 | 11/25/2022 | View on chart |
| PMVP | ▲ Buy | Option Exercise | 4,000 | $13K | 4/20/2022 | View on chart |
| PMVP | ▼ Sell | Gift | 2,725 | $0 | 12/30/2021 | View on chart |
| PMVP | ▲ Buy | Option Exercise | 5,000 | $16K | 8/19/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Janux Therapeutics draws fresh attention amid valuation concerns
Recent articles have put Janux Therapeutics back in focus after a 110% price increase over the past period. Analysts note that the stock may appear overvalued given its rapid run, with target prices ranging from $14 to $75 and an average of $36.24. The discussion comes as the shares trade near the upper end of their 52‑week range. Market participants are watching the valuation debate closely.
Janux Therapeutics draws fresh attention amid valuation concerns. Recent articles have put Janux Therapeutics back in focus after a 110% price increase over the past period. Analysts note that the stock may appear overvalued given its rapid run, with target prices ranging from $14 to $75 and an average of $36.24. The discussion comes as the shares trade near the upper end of their 52‑week range. Market participants are watching the valuation debate closely.